209 related articles for article (PubMed ID: 15970552)
1. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1).
Suelves M; Vidal B; Ruiz V; Baeza-Raja B; Diaz-Ramos A; Cuartas I; Lluis F; Parra M; Jardi M; Lopez-Alemany R; Serrano AL; Munoz-Canoves P
Front Biosci; 2005 Sep; 10():2978-85. PubMed ID: 15970552
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo.
Lluís F; Roma J; Suelves M; Parra M; Aniorte G; Gallardo E; Illa I; Rodríguez L; Hughes SM; Carmeliet P; Roig M; Muñoz-Cánoves P
Blood; 2001 Mar; 97(6):1703-11. PubMed ID: 11238111
[TBL] [Abstract][Full Text] [Related]
3. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.
Koh TJ; Bryer SC; Pucci AM; Sisson TH
Am J Physiol Cell Physiol; 2005 Jul; 289(1):C217-23. PubMed ID: 15716324
[TBL] [Abstract][Full Text] [Related]
4. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
5. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
7. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
[TBL] [Abstract][Full Text] [Related]
8. Activation of the serine proteinase system in chronic kidney rejection.
Tang WH; Friess H; di Mola FF; Schilling M; Maurer C; Graber HU; Dervenis C; Zimmermann A; Büchler MW
Transplantation; 1998 Jun; 65(12):1628-34. PubMed ID: 9665081
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
10. The role of the plasminogen system in bone resorption in vitro.
Daci E; Udagawa N; Martin TJ; Bouillon R; Carmeliet G
J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.
Bryer SC; Fantuzzi G; Van Rooijen N; Koh TJ
J Immunol; 2008 Jan; 180(2):1179-88. PubMed ID: 18178858
[TBL] [Abstract][Full Text] [Related]
14. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.
Sisson TH; Nguyen MH; Yu B; Novak ML; Simon RH; Koh TJ
Blood; 2009 Dec; 114(24):5052-61. PubMed ID: 19812386
[TBL] [Abstract][Full Text] [Related]
17. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Leloup G; Lemoine P; Carmeliet P; Vaes G
J Bone Miner Res; 1996 Aug; 11(8):1146-57. PubMed ID: 8854251
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
Okada SS; Grobmyer SR; Barnathan ES
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
[TBL] [Abstract][Full Text] [Related]
19. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
20. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
